A phase 2 clinical trial in mild-moderate AD showed decreased CSF levels of t-tau, p-tau, IL-6, IL-1β, and TNFα [260], and another phase 2 trial is currently ongoing (Table 3). The gene discussed is MAPT; the disease is Alzheimer disease.